Cost-effectiveness analysis of first-line gifitinib plus pemetrexed-platinum-based chemotherapy versus gifitinib monotherapy in EGFR-mutated NSCLC patients with brain metastases
Authors:
Open Access
- 27 August 2025
- journal article
- research article
- Published by Springer Nature in BMC Health Services Research
- Vol. 25 (1) , 1-9
Abstract
Brain metastases (BrMs) frequently manifest in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and the optimal treatment approach for these individuals remains controversial. This study aimed to evaluate the cost-effectiveness of adding pemetrexed-platinum chemotherapy to first-line gefitinib in EGFR-mutant NSCLC patients with BrMs, considering the perspective of the Chinese healthcare system. Constructing a Markov model, we simulated disease progression over a 10-year horizon in 4-week intervals. The model included three main health states: progression-free survival (PFS), progressive disease (PD), and death, along with a temporary PFS health state. Transition probabilities were estimated based on the data from the GAP BRAIN trial. Costs and utilities were collected from local public database and literature. One-way and probabilistic sensitivity analyses were employed to assess the robustness of the model. In the base case analysis, adding pemetrexed-platinum chemotherapy to first-line gefitinib resulted in an incremental effectiveness of 0.59 quality-adjusted life years (QALYs) and an increase in healthcare costs by $12,298.51. Consequently, the incremental cost-effectiveness ratio (ICER) amounted to $24,887.67/QALY, which fell below the prespecified willingness-to-pay (WTP) threshold of $37,654.50 per QALY. Deterministic sensitivity analysis indicated that, apart from the utility value of the PFS health state of the gefitinib plus chemotherapy (GPP) group, other parameters exerted minimal influence on the results. The probabilistic sensitivity analysis demonstrated that, at the predefined WTP threshold, the combination of gefitinib and chemotherapy was a cost-effective treatment strategy. Adding pemetrexed-platinum chemotherapy to first-line gefitinib for EGFR-mutant NSCLC patients with BrMs in China represented a cost-effective treatment strategy from the perspective of the Chinese healthcare system.Keywords
All Related Versions
Funding Information
- Henan Provincial Medical Science and Technology Key Research Project (RKX202401006)
This publication has 21 references indexed in Scilit:
- Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non–Small Cell Lung Cancer in Patients With Brain MetastasesJAMA Network Open, 2023
- The spatial transcriptomic landscape of non-small cell lung cancer brain metastasisNature Communications, 2022
- Icotinib versus whole-brain irradiation in patients with EGFR -mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trialThe Lancet Respiratory Medicine, 2017
- High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastasesJournal of Neuro-Oncology, 2017
- EGFR mutation status on brain metastases from non-small cell lung cancerLung Cancer, 2016
- Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancersLung Cancer, 2015
- Metastatic sites and survival in lung cancerLung Cancer, 2014
- EGFR Mutation and Brain Metastasis in Pulmonary AdenocarcinomasJournal of Thoracic Oncology, 2014
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRNew England Journal of Medicine, 2010